Report Description Table of Contents How Is the Global Diverticulitis Market Evolving Through Advanced Treatment Approaches and Healthcare Innovation? – (Updated On: 3rd-Nov-2026) According to Strategic Market Research, the Global Diverticulitis Market was valued at USD 3.53 billion in 2025 and is projected to reach USD 5.37 billion by 2032, growing at a CAGR of 6.2% during 2026–2032. Market demand is supported by a large underlying diverticulosis population, frequent outpatient and hospital care, and continued need for imaging, antibiotics in selected patients, interventional procedures, and surgery. The large concentration of diverticulosis among older adults creates a substantial patient pool for diverticulitis diagnosis and treatment, particularly as prevalence rises sharply with age. More than 50% of Americans over age 60 have diverticulosis, increasing to over 70% by age 80, although fewer than 5% are estimated to progress to diverticulitis. The United States represents a substantial diverticulitis treatment population, with more than 2.7 million outpatient visits and approximately 200,000 inpatient admissions each year. This level of healthcare utilization supports sustained demand for diagnostic imaging, physician consultations, hospital treatment, interventional procedures, and surgery, particularly among patients with recurrent or complicated disease. Diverticulitis is increasingly being diagnosed beyond the traditional older-adult population, widening the potential treatment base. UCLA Health reported a 52% increase in complicated early-onset diverticulitis among patients under 50 between 2005 and 2020, indicating growing demand for diagnostic imaging, hospital care, and specialist management among younger adults as well as older patients. Treatment is increasingly tailored to disease severity. Routine antibiotics are no longer recommended for every low-risk uncomplicated case, while patients with severe or complicated disease may require antibiotics, image-guided abscess drainage, hospitalization, or surgery. Larger abscesses are commonly managed with percutaneous drainage, while recurrent or severe disease can lead to sigmoid resection. This keeps hospital-based procedures and surgical care commercially important despite more selective drug use in mild cases. The pipeline remains relatively limited compared with other gastrointestinal diseases, but new approaches are emerging. Mikrobiomik's MBK-01 is being evaluated in the Phase II DIREBIOT program for recurrent uncomplicated diverticulitis, reflecting growing interest in microbiota-based treatment. Research is also exploring AI-assisted CT analysis to improve disease classification and support more consistent treatment decisions. Overall, the market's projected growth to USD 5.37 billion by 2032 is expected to come primarily from sustained healthcare utilization rather than a large wave of new drug approvals. The strongest opportunities remain in diagnostic imaging, selective anti-infective treatment, interventional radiology, colorectal surgery, hospital care, and emerging microbiome-based therapies, particularly as diagnosis increases among both older adults and younger patients with complicated disease. Which Diverticulitis Market Segments Are Leading and Emerging as the Fastest-Expanding Opportunities? By Treatment Type: Selective Antibiotic Use and Image-Guided Abscess Intervention Leading Segment: Antibiotic Therapy Antibiotic therapy accounted for the largest share of the global diverticulitis market, representing approximately 39% and generating USD 1.377 billion in 2025, with a projected CAGR of 4.5% during 2026–2032. However, evolving clinical guidelines increasingly support selective antibiotic use, as clinical trials demonstrate comparable recovery outcomes in mild, uncomplicated diverticulitis managed without antibiotics. Consequently, antibiotic prescribing is becoming more concentrated in complicated diverticulitis, immunocompromised patients, and individuals with systemic infections, reflecting a shift toward targeted treatment and evidence-based clinical decision-making. Fastest-Growing Segment: Percutaneous Abscess Drainage Percutaneous abscess drainage accounted for an estimated 9% of the global diverticulitis market, valued at USD 0.318 billion in 2025, and is projected to register the fastest CAGR of 8.2% during 2026–2032. The procedure is increasingly utilized to manage complicated acute diverticulitis involving localized abscess formation. Its minimally invasive approach enables targeted drainage of infected fluid collections, potentially reducing the need for emergency surgery. Growing clinical preference for image-guided interventions and improved management of diverticular abscesses support its expanding role in diverticulitis treatment. By Disease Type: Outpatient Case Volumes and Complication-Related Treatment Spending Leading Segment: Uncomplicated Diverticulitis Uncomplicated diverticulitis accounted for the largest share of the global Diverticulitis Market, contributing approximately 49%, equivalent to USD 1.730 billion in 2025, and is projected to grow at a CAGR of 5.4% during 2026–2032. Representing approximately 80%–85% of acute diverticulitis cases, uncomplicated diverticulitis is the most common and clinically less severe presentation. Its high prevalence, increasing outpatient treatment, wider use of diagnostic imaging, and growing preference for conservative management are supporting treatment activity across hospitals, gastroenterology clinics, and ambulatory healthcare settings. Fastest-Growing Segment: Complicated Diverticulitis Complicated diverticulitis accounted for an estimated 34% of the global Diverticulitis Market, valued at USD 1.200 billion in 2025, and is projected to register the fastest CAGR of 7.1% during 2026–2032. Its clinical significance stems from severe complications, including abscess formation, perforation, fistulas, and bowel obstruction, which frequently require hospitalization, intravenous antibiotics, drainage procedures, or surgical intervention. Increasing emphasis on timely diagnosis, advanced imaging, minimally invasive surgery, and post-treatment monitoring is strengthening treatment expenditure across hospitals and specialized gastrointestinal care centers. By Drug Class: Targeted Infection Control and Supportive Gastrointestinal Care Leading Segment: Antibiotics Antibiotics accounted for the largest estimated 58% share of drug-class-attributed Diverticulitis Market value, equivalent to USD 2.047 billion in 2025, and are projected to grow at a CAGR of 5.2% during 2026–2032. Antibiotic utilization varies according to disease severity, with selective prescribing for uncomplicated diverticulitis and routine administration for complicated cases involving abscesses, perforation, or systemic infection. Hospital-based intravenous antibiotic treatment, followed by oral therapy when clinically appropriate, remains an important component of managing severe diverticulitis and associated infectious complications. Fastest-Growing Segment: Other Supportive Medications Other supportive medications accounted for an estimated 15% market share, valued at USD 0.529 billion in 2025, and are projected to register the fastest CAGR of 9.1% during 2026–2032. Within the diverticulitis market, supportive medications play an important role in managing abdominal discomfort, bowel irregularities, and associated gastrointestinal symptoms. Growing clinical emphasis on symptom management, digestive recovery, and prevention of recurrent episodes is supporting the use of adjunctive therapies alongside primary treatment, particularly among patients requiring continued gastrointestinal care and post-treatment monitoring. By Route of Administration: Oral Outpatient Treatment and Intravenous Acute Care Leading Segment: Oral Administration Oral administration dominated the global Diverticulitis Market, accounting for an estimated 61% share, valued at USD 2.153 billion in 2025, and is projected to grow at a CAGR of 5.4% during 2026–2032. The widespread use of oral antibiotics, including amoxicillin-clavulanate, for selected patients requiring antibiotic treatment supports its leading position. Outpatient management of uncomplicated diverticulitis, lower treatment costs, and patient preference for convenient medication options further strengthen oral administration's role in clinical care, particularly among patients who can avoid hospitalization. Fastest-Growing Segment: Intravenous Administration Intravenous (IV) administration accounted for an estimated 39% of the global Diverticulitis Market, valued at USD 1.377 billion in 2025, and is projected to register the fastest CAGR of 7.4% during 2026–2032. IV administration remains essential for managing complicated diverticulitis, severe infections, and patients unable to tolerate oral medications. Increasing hospital admissions for diverticular complications, including abscesses and perforations, support the use of intravenous antibiotics, fluids, and supportive therapies, strengthening its importance in hospital-based diverticulitis treatment and acute care management. By Treatment Setting: Home-Based Recovery and Complex Hospital Admissions Leading Segment: Outpatient Care Outpatient care dominated the global Diverticulitis Market with an estimated 56% share, valued at USD 1.977 billion in 2025, and is projected to expand at a CAGR of 5.9% during 2026–2032. Approximately 85%–90% of patients with acute uncomplicated diverticulitis can be safely managed through outpatient treatment, particularly those without abscesses, perforation, or intestinal obstruction. Increasing preference for home-based recovery, reduced hospitalization costs, and wider adoption of outpatient clinical management are supporting the expansion of diverticulitis treatment services across healthcare facilities. Fastest-Growing Segment: Inpatient Care Inpatient care accounted for an estimated 44% of the global diverticulitis market, valued at USD 1.553 billion in 2025, and is projected to register the fastest CAGR of 6.6% during 2026–2032. Hospitalization is primarily required for patients experiencing complicated diverticulitis, severe abdominal pain, inability to tolerate oral fluids, or serious infections. Older adults and immunocompromised patients also frequently require inpatient monitoring and treatment. Increasing cases of complicated diverticulitis, alongside the need for intravenous antibiotics, emergency surgery, and specialized hospital care, support continued market expansion. By End User: Hospital-Based Complication Management and Ambulatory Procedures Leading Segment: Hospitals Hospitals accounted for the largest estimated share of the global Diverticulitis Market at 67%, valued at USD 2.365 billion in 2025, and are projected to expand at a CAGR of 5.9% during 2026–2032. Hospitals play a central role in diverticulitis management through emergency diagnosis, inpatient supportive care for moderate-to-severe and complicated cases, intravenous antibiotic administration, abscess drainage, and surgical interventions. Increasing hospital admissions for complicated diverticulitis, particularly among older adults, continue to support hospital-based treatment expenditure and specialized gastrointestinal care services. Fastest-Growing Segment: Ambulatory Surgical Centers Ambulatory Surgical Centers (ASCs) accounted for an estimated 10% of the global diverticulitis market, valued at USD 0.353 billion in 2025, and are projected to register the fastest CAGR of 7.4% during 2026–2032. ASCs primarily support diagnostic evaluations, colonoscopy procedures, and selected elective surgical interventions for patients with diverticulitis. Increasing preference for outpatient procedures, shorter recovery periods, and cost-effective surgical care is supporting their expanding role in managing uncomplicated and appropriately selected recurrent diverticulitis cases, particularly among clinically stable patients. By Geography: North American Treatment Expenditure and Expanding Asian Diagnostic Access Leading Region: North America North America dominated the global Diverticulitis Market, accounting for the largest estimated share of 39%, equivalent to USD 1.377 billion in 2025, and is projected to grow at a CAGR of 5.4% during 2026–2032. Diverticulitis remains a significant gastrointestinal condition contributing to hospital admissions and healthcare expenditures across the region. The growing prevalence of diverticular disease, increasing elderly population, advanced diagnostic capabilities, and greater utilization of hospital-based treatments, including antibiotic therapy and surgical interventions, continue to support market expansion across the United States and Canada. Fastest-Growing Region: Asia-Pacific Asia-Pacific Diverticulitis Market accounted for an estimated 23% of the global market, valued at USD 0.812 billion in 2025, and is projected to expand at the fastest regional CAGR of 7.4% during 2026–2032. Diverticulitis has evolved from a historically uncommon gastrointestinal condition into an increasingly recognized diagnosis across the region. Rising disease prevalence, aging populations, improved diagnostic access, and greater utilization of colonoscopy and abdominal imaging are contributing to earlier identification, increased treatment activity, and expanding opportunities for gastrointestinal healthcare providers. How Are New and Emerging Treatment Options Transforming Diverticulitis Management? Selective Antibiotic-Free Treatment for Uncomplicated Diverticulitis Selective antibiotic-free management is changing the treatment of mild, uncomplicated diverticulitis. Rather than routinely prescribing antibiotics, clinicians increasingly use hydration, symptom control, dietary adjustments, and clinical monitoring for suitable patients with healthy immune systems. The 2026 American College of Gastroenterology guidelines support avoiding routine antibiotics in low-risk uncomplicated cases, while recommending antibiotics for patients with high-risk features, frailty, or weakened immunity. This approach can reduce unnecessary antibiotic exposure, medication-related complications, and treatment costs. Commercially, it supports a gradual shift toward outpatient consultation, diagnostic assessment, and supportive care, while preserving antibiotic utilization in complicated cases. Endoscopic Ultrasound-Guided Abscess Drainage Endoscopic ultrasound-guided abscess drainage is emerging as a specialized minimally invasive treatment for complicated diverticulitis. The procedure uses ultrasound-guided endoscopic instruments to drain selected pelvic or nearby abscesses through the gastrointestinal tract, particularly when conventional percutaneous drainage is difficult. A 2025 multicenter study involving 53 patients reported a 92.5% technical success rate and 88.7% clinical success rate, with adverse events occurring in 3.8% of patients. These findings demonstrate its potential as an alternative intervention in selected patients, although larger comparative studies are required. This technique creates specialized opportunities for endoscopic ultrasound equipment, drainage stents, and advanced therapeutic endoscopy services. Laparoscopic Sigmoid Resection with Enhanced Recovery Protocols Laparoscopic sigmoid resection combined with enhanced recovery pathways is improving surgical management for selected patients with recurrent or complicated diverticulitis. The procedure removes the affected portion of the colon through smaller incisions, while enhanced recovery protocols emphasize optimized anesthesia, early mobilization, appropriate pain management, and earlier nutritional recovery. Evidence from the LASER randomized clinical trial showed that recurrent diverticulitis occurred in 11% of surgically treated patients versus 61% of conservatively treated patients within two years, among patients included in the reported recurrence analysis. These developments support investment in minimally invasive surgical instruments, advanced operating-room technologies, and recovery-focused hospital services, particularly where patients experience persistent symptoms or repeated episodes. Image-Guided Percutaneous Abscess Drainage Image-guided percutaneous abscess drainage is an established minimally invasive intervention that continues to evolve through improved imaging and catheter technologies. Interventional radiologists use CT or ultrasound guidance to place drainage catheters into accessible infected collections, generally alongside antibiotic therapy. The 2026 American Society of Colon and Rectal Surgeons guidelines recommend considering image-guided drainage for diverticular abscesses larger than 4 cm or in patients experiencing clinical deterioration. Successful drainage may help control infection and avoid immediate emergency surgery in selected cases. This treatment supports commercial opportunities for image-guided intervention systems, drainage catheters, and specialized interventional radiology services. Personalized Elective Surgery Based on Disease Severity and Quality of Life Personalized elective surgery represents an important shift from episode-count-based decisions toward patient-specific treatment planning. Clinicians increasingly consider persistent symptoms, recurrent hospitalizations, complications, immune status, operative risks, and the patient's quality of life before recommending sigmoid resection. The 2025 four-year LASER trial follow-up, involving 90 randomized patients, found that 32% of patients initially assigned to conservative treatment subsequently underwent sigmoid resection, highlighting the importance of persistent symptoms and patient preferences in surgical decisions. This approach encourages targeted surgical intervention for patients most likely to benefit, supporting efficient hospital resource allocation and personalized colorectal care. It also creates opportunities for specialized surgical centers and advanced minimally invasive technologies Which Leading Companies Are Shaping the Global Diverticulitis Treatment Market? Medtronic plc: Colorectal Stapling and Vessel-Sealing Technologies in Surgical Care Medtronic plc is a major medical technology participant in the diverticulitis treatment market, particularly through its surgical and endoscopy portfolio supporting colorectal procedures. Its surgical stapling, vessel-sealing, and minimally invasive technologies are relevant to sigmoid colectomy and other interventions used for selected patients with complicated or recurrent diverticulitis. According to its official financial disclosures, Medtronic generated USD 8.815 billion in Medical Surgical revenue in fiscal 2026, increasing approximately 4.9% from USD 8.407 billion in fiscal 2025. Its Surgical & Endoscopy division contributed USD 6.764 billion in fiscal 2026, compared with USD 6.498 billion in fiscal 2025. These figures demonstrate the company's substantial surgical technology business, although they encompass multiple procedures and are not diverticulitis-specific sales. Medtronic's LigaSure vessel-sealing technology and advanced surgical stapling portfolio support procedures requiring tissue dissection, vessel sealing, and intestinal reconstruction. Increasing adoption of minimally invasive colorectal surgery creates commercial opportunities for these technologies, especially in hospitals investing in surgical efficiency and improved patient recovery. Other Key Companies and Their Roles: Pfizer Inc.: Supplies antimicrobial pharmaceuticals relevant to bacterial infections, including antibiotic treatment pathways for complicated diverticulitis. Merck & Co., Inc.: Participates through antibacterial medicines, including ertapenem, used for appropriate complicated intra-abdominal infections. Sandoz Group AG: Provides generic antibiotics and other established medicines that support cost-sensitive pharmaceutical procurement and diverticulitis treatment. Fresenius Kabi AG: Supplies injectable pharmaceutical products and infusion therapies relevant to inpatient management of severe or complicated diverticulitis. Johnson & Johnson MedTech: Through its Ethicon surgical portfolio, provides stapling, energy, and minimally invasive surgical technologies relevant to colorectal resections. Analyst Commentary: Where Are Minimally Invasive Interventions Creating Higher-Value Opportunities? The diverticulitis market presents stronger commercial opportunities in minimally invasive interventions and complicated disease management than in routine antibiotic therapy. Competitive advantage will increasingly depend on reducing hospital stays, improving procedural outcomes, and demonstrating cost-effectiveness. Companies offering advanced surgical technologies and efficient treatment solutions are better positioned to capture higher-value healthcare spending. Diverticulitis Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 3.53 Billion Revenue Forecast in 2032 USD 5.37 Billion Overall Growth Rate CAGR of 6.2% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million/Billion, CAGR (2026 – 2032) Segmentation By Treatment Type, By Disease Type, By Drug Class, By Route of Administration, By Treatment Setting, By End User, By Geography By Treatment Type Antibiotic Therapy, Supportive and Symptomatic Treatment, Surgical Treatment, Percutaneous Abscess Drainage By Disease Type Uncomplicated Diverticulitis, Complicated Diverticulitis, Recurrent Diverticulitis By Drug Class Antibiotics, Analgesics, Other Supportive Medications By Route of Administration Oral Administration, Intravenous Administration By Treatment Setting Outpatient Care, Inpatient Care By End User Hospitals, Specialty Clinics, Ambulatory Surgical Centers By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Substantial outpatient and inpatient treatment demand, aging populations with diverticulosis, increasing complicated disease among younger adults, continued need for surgery and abscess drainage, long-term management of recurrent diverticulitis Customization Option Available upon request Frequently Asked Question About This Report Q1. How are changing treatment practices influencing the market? A1. Care is becoming more closely tailored to disease severity. Selective antibiotic use in low-risk uncomplicated cases changes the prescription opportunity. Meanwhile, severe infections and complications continue to generate demand for hospital care and procedural treatment. Q2. Which procedures offer the strongest growth opportunities in the market? A2. Percutaneous abscess drainage is projected to grow at a CAGR of 8.2% during 2026–2032, the fastest among treatment categories. Image-guided intervention creates opportunities in selected complicated cases. Surgical treatment also remains commercially important, with projected annual growth of 7.7%. Q3. What emerging developments could influence the industry? A3. Microbiota-based treatments are being investigated for recurrent uncomplicated disease, including Mikrobiomik’s MBK-01 program. Research into AI-assisted CT analysis could also support disease classification. These remain development opportunities, with commercial uptake dependent on evidence and integration into clinical care. Q4. Why does outpatient care hold the largest market share? A4. Many uncomplicated cases can be managed through consultations and conservative care outside inpatient settings. Outpatient services account for an estimated 56% revenue share in 2025. Follow-up visits and monitoring also create continuing demand among patients with recurrent symptoms. Q5. Which patient group is generating faster spending growth in the market? A5. Complicated disease is projected to grow at a CAGR of 7.1% during 2026–2032. These patients can require hospitalization and more intensive interventions. Higher spending on imaging, drainage and surgery makes this group important to specialist providers despite its smaller share than uncomplicated disease. Q6. What factors could limit pharmaceutical revenue growth in the industry? A6. More selective antibiotic prescribing can restrict medicine demand in mild cases. The relatively limited pipeline also means growth depends heavily on established treatments. Pharmaceutical forecasts should therefore distinguish patients requiring infection treatment from those managed primarily through supportive care or procedures. Q7. How do regional opportunities differ across the market? A7. North America leads with an estimated 39% revenue share in 2025 through established gastrointestinal services and substantial healthcare spending. Asia-Pacific is projected to grow fastest at a CAGR of 7.4% during 2026–2032 as diagnostic access and specialized surgical capabilities expand. Sources: U.S. NIDDK — More Than 70% of Americans Older Than 80 Have Diverticulosis, While Fewer Than 5% of People With Diverticulosis Develop Diverticulitis NIDDK — Diverticular Disease: Prevalence, Progression, and Approximately 200,000 Annual Diverticulitis Hospitalizations Gastroenterology — Reports That More Than 50% of Americans Older Than 60 Have Diverticulosis PubMed Central — Epidemiology, Pathophysiology, and Treatment of Diverticulitis U.S. NIDDK — Recorded 2.7 Million Ambulatory Visits for Diverticular Disease in 2009 NIDDK — U.S. Digestive Disease Statistics: Diverticular Disease Healthcare Utilization UCLA — Patients Under 50 Increased From 18.5% to 28.2% of Complicated-Diverticulitis Admissions Between 2005 and 2020 UCLA — Analysis of More Than 5.2 Million Hospitalizations Identifies a Shift Toward Younger Patients JAMA — A 2025 Review Reports That Approximately 85% of Acute Diverticulitis Cases Are Uncomplicated PubMed — Diverticulitis: Disease Burden, Uncomplicated Cases, Diagnosis, and Treatment American College of Gastroenterology — July 2026 Guidelines Recommend Against Routine Antibiotics for Low-Risk Uncomplicated Diverticulitis ACG — Colonic Diverticulitis Guidelines: Selective Antibiotics, Imaging, and Surgical Consultation American Society of Colon and Rectal Surgeons — October 2026 Guidelines Recommend Considering Image-Guided Drainage for Diverticular Abscesses Larger Than 4 cm or Clinical Deterioration ASCRS — Updated Management of Left-Sided Colonic Diverticulitis UK NICE — Identifies Oral Co-Amoxiclav as a First-Choice Antibiotic When Antibiotic Treatment Is Required for Uncomplicated Acute Diverticulitis NICE — Diverticular Disease Recommendations: Oral and Intravenous Antibiotic Treatment U.S. NIDDK — Distinguishes Home Treatment for Uncomplicated Diverticulitis From Hospital Treatment, Abscess Drainage, and Surgery for Severe or Complicated Disease NIDDK — Diverticulitis Treatment Settings, Supportive Care, Drainage, and Colectomy Mikrobiomik — Reports That Its Phase IIa Microbiota-Based Treatment Study for Recurrent Diverticulitis Began Recruiting Patients in April 2025 Mikrobiomik — Recurrent Diverticulitis Clinical Programme and Investigational Oral Microbiota Therapy Gastrointestinal Endoscopy — A 2025 Study of 53 Patients Reported 92.5% Technical Success and 88.7% Clinical Success With Endoscopic Ultrasound-Guided Abscess Drainage PubMed — Endoscopic Drainage With Lumen-Apposing Metal Stents for Complicated Acute Diverticulitis JAMA Surgery — Two-Year LASER Trial Analysis Reported Diverticulitis Recurrence in 11% of Surgical Patients Versus 61% of Conservatively Managed Patients PubMed — Laparoscopic Sigmoid Resection Versus Conservative Treatment: Two-Year Outcomes JAMA Surgery — Four-Year LASER Follow-Up Found That 32% of Patients Initially Assigned to Conservative Treatment Subsequently Underwent Sigmoid Resection JAMA Surgery — April 2025 Publication: Four-Year Results From the 90-Patient LASER Trial Clinical Gastroenterology and Hepatology — A 2026 Study Used Automated Analysis of CT Reports to Classify Diverticulitis Complications and Predict Severe Recurrence PubMed Central — Natural Language Processing for Diverticulitis Classification and Long-Term Outcomes Medtronic — Reported Fiscal 2026 Medical Surgical Revenue of USD 8.815 Billion, Including USD 6.764 Billion From Surgical & Endoscopy Medtronic — June 2026 Financial Results and Surgical Business Revenue Medtronic — Lists Colectomy Among Procedures Supported by Its LigaSure Blunt Tip Sealer-Divider Medtronic — LigaSure Surgical Applications and Colectomy Relevance Johnson & Johnson MedTech — Identifies Diverticulitis as an Indication for Laparoscopic Sigmoid Colectomy J&J MedTech — Laparoscopic Sigmoid Colectomy and Diverticulitis Surgical Management Table of Contents - Global Diverticulitis Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Treatment Type, Disease Type, Drug Class, Route of Administration, Treatment Setting, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Treatment Type, Disease Type, Drug Class, Route of Administration, Treatment Setting, End User, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Treatment Type, Disease Type, Drug Class, Route of Administration, Treatment Setting, and End User Investment Opportunities in the Diverticulitis Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Diagnostic Imaging, Selective Anti-Infective Treatment, Interventional Radiology, Colorectal Surgery, Hospital Care, and Microbiome-Based Therapies Emerging Opportunities in AI-Assisted CT Analysis and Microbiota-Based Treatment Research Investment Potential in Minimally Invasive Abscess Drainage and Laparoscopic Surgical Technologies Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Clinical Overview of Diverticulitis and Its Relationship with Diverticulosis Strategic Importance of Diverticulitis Management in Gastrointestinal Care, Infection Control, Imaging, and Colorectal Surgery Role of Outpatient Management, Hospitalization, Interventional Procedures, and Surgical Treatment Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Historical Market Assessment (2019–2024) Base Year Evaluation (2025) Forecast Modeling and Market Outlook (2026–2032) Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Clinical Guidelines and Public Healthcare Practices Role of Selective Antibiotic Use, Supportive Care, and Surgical Intervention in Market Expansion Increasing Demand for Diagnostic Imaging, Hospital Treatment, and Colorectal Surgery Influence of Aging Populations and Diverticulosis Prevalence on Treatment Demand Growing Recognition of Complicated Early-Onset Diverticulitis Emerging Microbiome-Based Therapies and AI-Assisted CT Analysis Global Diverticulitis Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type: Antibiotic Therapy Supportive and Symptomatic Treatment Surgical Treatment Percutaneous Abscess Drainage Market Analysis by Disease Type: Uncomplicated Diverticulitis Complicated Diverticulitis Recurrent Diverticulitis Market Analysis by Drug Class: Antibiotics Analgesics Other Supportive Medications Market Analysis by Route of Administration: Oral Administration Intravenous Administration Market Analysis by Treatment Setting: Outpatient Care Inpatient Care Market Analysis by End User: Hospitals Specialty Clinics Ambulatory Surgical Centers Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Diverticulitis Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Disease Type, Drug Class, Route of Administration, Treatment Setting, and End User Regional Treatment Trends, Diagnostic Imaging Utilization, and Colorectal Surgical Care Country-Level Breakdown: United States Canada Mexico Europe Diverticulitis Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Disease Type, Drug Class, Route of Administration, Treatment Setting, and End User Regional Trends in Aging Populations, Gastrointestinal Care, and Specialized Colorectal Treatment Country-Level Breakdown: Germany United Kingdom France Italy Rest of Europe Asia-Pacific Diverticulitis Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Disease Type, Drug Class, Route of Administration, Treatment Setting, and End User Regional Trends in Diagnostic Capabilities, Gastrointestinal Care Access, and Surgical Modernization Country-Level Breakdown: China Japan Other Asia-Pacific Markets Latin America Diverticulitis Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Disease Type, Drug Class, Route of Administration, Treatment Setting, and End User Regional Trends in Diagnostic Imaging Access and Specialized Hospital Services Country-Level Breakdown: Brazil Mexico Rest of Latin America Middle East & Africa Diverticulitis Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Disease Type, Drug Class, Route of Administration, Treatment Setting, and End User Regional Trends in Hospital Infrastructure, Gastroenterology Services, and Minimally Invasive Surgical Capabilities Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Medtronic plc Pfizer Inc. Merck & Co., Inc. Sandoz Group AG Fresenius Kabi AG Johnson & Johnson MedTech Becton, Dickinson and Company Boston Scientific Corporation Olympus Corporation Siemens Healthineers AG GE HealthCare Technologies Inc. Philips Intuitive Surgical, Inc. Mikrobiomik Abbott Laboratories Competitive Landscape and Strategic Insights Benchmarking Based on Surgical Technologies, Antibiotic Portfolios, Diagnostic Imaging, Interventional Devices, and Regional Presence Supplier Qualification and Regulatory Compliance Capability Analysis Colorectal Surgical Technology and Minimally Invasive Procedure Positioning Antibiotic Portfolio and Selective Treatment Strategy Analysis Diagnostic Imaging and AI-Assisted CT Analysis Capabilities Microbiome-Based Therapeutic Research and Emerging Treatment Competitiveness Appendix Abbreviations and Terminologies Used in the Report References and Sources Clinical Guidelines and Treatment Approaches Relevant to Diverticulitis Management List of Tables Market Size by Treatment Type, Disease Type, Drug Class, Route of Administration, Treatment Setting, End User, and Region (2026–2032) Historical Market Size and Volume (2019–2024), Base Year Market Size Analysis (2025), and Market Forecasts (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Country-Level Market Breakdown Across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa Competitive Benchmarking of Leading Vendors Antibiotic Therapy, Supportive Care, Surgical Treatment, and Percutaneous Abscess Drainage Analysis Diagnostic Imaging, Interventional Radiology, and Colorectal Surgery Technology Analysis Emerging Microbiome-Based Therapies and AI-Assisted CT Analysis List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Treatment Type, Disease Type, Drug Class, Route of Administration, Treatment Setting, and End User (2025 vs. 2032) Global Diverticulitis Treatment Ecosystem and Value Chain Analysis Outpatient and Inpatient Treatment Pathways Minimally Invasive Abscess Drainage and Colorectal Surgical Treatment Trends